ABSTRACT
INTRODUCTION: To describe microureteroscopy, a novel minimally invasive approach for treating distal ureteral lithiasis. TECHNICAL CONSIDERATIONS: Seven female patients with distal ureteral stones ≤ 10 mm were operated by microureteroscopy. The microureteroscope consist on a 4.85 Fr (16-gauge) sheath, a 0.9 mm diameter flexible optic system, and a 3-arm Luer-lock adapter to connect the sheath and insert the optics. Patients are placed in lithotomy position. Under sedative anesthesia and antimicrobial coverage, we performed microureteroscopy in patients with distal ureteral stones, describing key steps and perioperative and postoperative outcomes. Stone clearance was assessed using X-ray plain abdominal film of KUB at 15 days. Mean patients age was 54.5 years, and mean stone size was 7.98 mm. Stone-free rate was 100%. Patients were discharged 2-4 hours after the procedure without intraoperative or major perioperative complications. CONCLUSION: Microureteroscopy was developed to reduce dilation and ureteral wall damage and, thus, to decrease postoperative stenting and hospital stay.
Subject(s)
Ambulatory Surgical Procedures , Minimally Invasive Surgical Procedures , Ureteral Calculi/surgery , Ureteroscopy/methods , Adult , Aged , Female , Fluoroscopy , Humans , Middle Aged , Retrospective Studies , Tomography, X-Ray Computed , Ureteral Calculi/diagnostic imaging , Young AdultSubject(s)
Foreign Bodies/complications , Penile Prosthesis , Prosthesis Failure/etiology , Humans , Male , Middle AgedABSTRACT
Retrorectal cystic hamartoma (tailgut cyst) is a rare congenital lesion. This study is one of the few reports of this rare clinical entity causing irritative voiding symptoms and constipation in a male patient. Although most cases are asymptomatic, patients may present with symptoms resulting from local mass effect or complication.
Subject(s)
Constipation/etiology , Hamartoma/complications , Rectal Diseases/complications , Urination Disorders/etiology , Humans , Male , Middle AgedABSTRACT
A 45 year old male was referred to our clinic after an episode of acute prostatitis six weeks before, treated with ciprofloxacin for one month. Genital examination was normal with prostate slightly painful on DRE.
Subject(s)
Abscess/etiology , Genital Diseases, Male/etiology , Prostatitis/complications , Seminal Vesicles , Acute Disease , Humans , Male , Middle AgedABSTRACT
No disponible
Subject(s)
Humans , Male , Urology/education , Urology/methods , Abscess/diagnosis , Abscess/metabolism , Seminal Vesicles/abnormalities , Seminal Vesicles/pathology , Therapeutics/methods , Anti-Bacterial Agents/administration & dosage , Urology/instrumentation , Urology , Abscess/complications , Abscess/prevention & control , Seminal Vesicles/metabolism , Seminal Vesicles , Therapeutics/standards , Anti-Bacterial Agents/metabolismABSTRACT
No disponible
Subject(s)
Humans , Male , Penile Erection/genetics , Rupture/complications , Rupture/metabolism , Ambulatory Care/methods , Ambulatory Care/psychology , Hematoma/congenital , Hematoma/complications , Urethral Diseases/pathology , Catheters/classification , Penile Erection/psychology , Rupture/genetics , Rupture/pathology , Ambulatory Care , Ambulatory Care , Hematoma/genetics , Hematoma/metabolism , Urethral Diseases/complications , CathetersABSTRACT
OBJECTIVES: To report the preliminary results of one of the first series of patients treated with a new simple surgical technique for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and to evaluate its safety and feasibility. METHODS: We have performed a novel surgical treatment of BPH, the UroLift® System (Neotract, Inc). It opens the urethra directly by retracting the obstructing prostatic lobes without applying incisions, surgical resection or thermal injury to the prostate. RESULTS: The procedure was carried out in 20 patients with a mean age of 74.3 (43 hyphen;-90) years, with mean prostate volume of 42.6 mL (19 hyphen;109) using the same operative protocol in all case subjects. Mean operative time was 19.1 min (range: 12-45). International Prostate Symptom Score (IPSS) ) at 4 weeks reduced from 26.7 to 16.7 and peak urinary flow rate (Qmax) increased from 8.6 mL/s to 13.2 mL/s. No major complications were encountered, neither sexual dysfunction. Mean follow-up: 12.3 (2-22) months. CONCLUSIONS: The UroLift® System procedure appears to be safe and efficient at short term. This technique minimizes the bleeding of the urethra and, therefore, makes bladder catheter not always necessary, and can preserve sexual function with low morbidity. Further studies are warranted to determine long-term outcome.
Subject(s)
Minimally Invasive Surgical Procedures/methods , Prostatic Hyperplasia/complications , Suburethral Slings , Urologic Diseases/etiology , Urologic Diseases/surgery , Urologic Surgical Procedures/methods , Adult , Aged , Aged, 80 and over , Anesthesia, Spinal , Humans , Male , Middle Aged , Minimally Invasive Surgical Procedures/adverse effects , Prostate/pathology , Urologic Surgical Procedures/adverse effectsABSTRACT
OBJETIVO: Presentar una de las primeras series de pacientes tratados con una nueva y sencilla técnica quirúrgica para los síntomas del tracto urinario inferior secundaria a HBP, evaluando su seguridad y eficacia con resultados preliminares. MÉTODOS: Se ha empleado una nueva técnica para el tratamiento quirúrgico de la HBP, el UroLift® System (Neotract, Inc.), que aumenta el calibre de la uretra prostática de forma directa, retrayendo los lóbulos prostáticos obstructivos sin realizar incisiones, resección quirúrgica o daño térmico sobre el tejido prostático. RESULTADOS: El procedimiento ha sido realizado sobre 20 pacientes (media edad: 74.3 años) con un volumen medio prostático de 42.6 cc. (19-109) y empleando el mismo protocolo en todos los casos. El tiempo medio de la intervención fue 19.1 min (7-45). La puntuación del International Prostate Symptom Score (IPSS) a las 4 semanas se redujo de 26.7 a 16.7 y el Flujo máximo (Qmax) se incrementó desde 8.6 mL/s hasta 13.2 mL/s. No se presentaron complicaciones mayores, ni afectación de la función sexual. Seguimiento medio: 12.3 (2-22) meses. CONCLUSIONES: El dispositivo UroLift® parece eficaz y seguro a corto plazo. Está nueva técnica minimiza el sangrado de la uretra prostática y, por tanto, no hace siempre necesario el empleo de sondaje vesical posterior. Además presenta una baja morbilidad, preservando la función sexual. Sin embargo debemos esperar los resultados de un número mayor de pacientes tratados mediante esta nueva técnica y con seguimientos más prolongados para extraer conclusiones más firmes (AU)
OBJECTIVES: To report the preliminary results of one of the first series of patients treated with a new simple surgical technique for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and to evaluate its safety and feasibility. METHODS: We have performed a novel surgical treatment of BPH, the UroLift® System (Neotract, Inc). It opens the urethra directly by retracting the obstructing prostatic lobes without applying incisions, surgical resection or thermal injury to the prostate. RESULTS:The procedure was carried out in 20 patients with a mean age of 74.3 (43-90) years, with mean prostate volume of 42.6 mL (19-109) using the same operative protocol in all case subjects. Mean operative time was 19.1 min (range: 12-45). International Prostate Symptom Score (IPSS) at 4 weeks reduced from 26.7 to 16.7 and peak urinary flow rate (Qmax) increased from 8.6 mL/s to 13.2 mL/s. No major complications were encountered, neither sexual dysfunction. Mean follow-up: 12.3 (2-22) months. CONCLUSIONS: The UroLift® System procedure appears to be safe and efficient at short term. This technique minimizes the bleeding of the urethra and, therefore, makes bladder catheter not always necessary, and can preserve sexual function with low morbidity. Further studies are warranted to determine long-term outcome (AU)
